Condition category
Not Applicable
Date applied
23/08/2007
Date assigned
23/08/2007
Last edited
17/09/2008
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Mr J P Trietsch

ORCID ID

Contact details

Maastricht University
Department of General Practice
P.O. Box 616
Maastricht
6200 MD
Netherlands
+31 (0)43 388 2877
Jasper.Trietsch@HAG.unimaas.nl

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

NTR1033

Study information

Scientific title

Acronym

Study hypothesis

This strategy will improve the number of tests ordered or the volume of prescribed drugs by 20% and decrease the inter-doctor variation.

Ethics approval

Approval received from the Ethics Board of the academic hospital Maastricht (azM)/Maastricht University (UM) on the 24th August 2006 (ref: MEC 06-4-033).

Study design

Multicentre, cluster-randomised, active controlled, parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

GP practices

Trial type

Treatment

Patient information sheet

Condition

Prescribing and test ordering performance of general practitioners

Intervention

All participating GP's receive feedback on their own test ordering and prescribing performance in the foregoing six months on a predefined clinical topic. The graphical comparative feedback is send to each GP individually together with an outline of current guidelines on the topic, prior to the group meeting. The feedback will lead to peer review, seeking and discussing explanations for differences, comparing own performance to the guidelines, discussing a plan for change and discussing barriers to change. Each group discusses three clinical topics in six sessions. If the group wishes to do so, two sessions (test ordering and prescribing) can be combined into one session.

The intervention will run from September 2007 through February 2009. Please note that as of 05/10/2007, the anticipated start date of this trial was posponed from September 2007 to December 2007.

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

1. The volume of ordered diagnostic tests and of prescribed medication
2. The inter-doctor variation in both test ordering and prescribing

Outcomes are measured at start of study (baseline), each 6 months preliminary data, after 18 months main timepoint for effect measurement, 6 and 12 months later long term effect measurement.

Secondary outcome measures

1. The quality of prescribing as defined by indicators
2. The level of functioning of the groups
3. What are the costs of implementation of the strategy?
4. Process data (attendance, altering of the meeting structure etc.)

Outcomes are measured at start of study (baseline), each 6 months preliminary data, after 18 months main timepoint for effect measurement, 6 and 12 months later long term effect measurement.

Overall trial start date

01/12/2007

Overall trial end date

01/02/2010

Reason abandoned

Eligibility

Participant inclusion criteria

Groups of General Practitioners (GPs) conjoint in pharmacotherapeutic audit groups.

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

50 groups

Participant exclusion criteria

1. Groups of over 15 GP's
2. Groups outside the provinces: Zeeland, Brabant or Limburg

Recruitment start date

01/12/2007

Recruitment end date

01/02/2010

Locations

Countries of recruitment

Netherlands

Trial participating centre

Maastricht University
Maastricht
6200 MD
Netherlands

Sponsor information

Organisation

University Maastricht (UM) (Netherlands)

Sponsor details

Department General Practitioner Medicine
P.O. Box 616
Maastricht
6200 MD
Netherlands
+31 (0)43 388 2309
trudy.vanderweijden@hag.unimaas.nl

Sponsor type

Hospital/treatment centre

Website

http://www.unimaas.nl/default.asp?taal=en

Funders

Funder type

Industry

Funder name

CZ Health Insurance Company (CZ Actief in Gezondheid) (Netherlands)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Funder name

The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes